team proud report have months today. joining you Health, the progress of I after am those call to to welcome and Bausch Judy, our management new over you, Nine we made. took Thank the
$X.XX XXXX, for guidance met full L. the of Health, $X.XX of we First, billion Bausch excluding and EBITDA + delivering the B billion year revenue for
EBITDA during are as growth said to delivering XXXX. and I and and I in revenue However, go forward. committed my calls, And team declined have as revenue we EBITDA prior
I Health, performance fourth Solta saw momentum with driven foundation encouraging X% in a for revenue We and Bausch B provides am XXXX. Salix, excluding L, in for basis, businesses. the line International up the this pleased believe our growth organic top we solid + by quarter with on
our Second, XXXX. to principal, our for billion alternatives, make improving Bausch continue + we + Health, in progress L, net $X.X on has reduced sheet. been excluding strategic unrestricted Debt now balance since May B Bausch cash by of IPO the Lomb of of
will vigorously continued We continuously, have to property. work also intellectual defend several our to and matters legacy resolve
outlook, providing our given momentum, will which we Third, for solid a confident create stakeholders. are XXXX value we long-term are
business take Salix quarter on Let the growth me you some care revenue the am fourth call. that Vadaketh our Slide long-term of the organic all pleased be business than in making of X. segments. script to will Xifaxan with channel, through Tom One, this on later encouraging progress specifics. in growth touch Starting report other performance in in X% channels the now I which we'll had
and diagnosis the the full a grew treatment GI in the of half Salix continue shown the first drive declining X% The Our to of It results. after and the and improve in has resulting half organically growth strategies liver commercial momentum to X% X% year. and year, year. in of targeted initiatives disease business second for
Relistor scripts mid-single-digit growth key by Plenvu led saw for for and growth double-digit increased also Other brands promoted and Trulance.
increase organic a brands Canada, on we with the as Poland, International, products. quarter, existing Mexico for business basis. grow organic X% markets year in and healthy to continue key the posted an The in new and International such growth X% For resulting
full year. XX% X% organic In growth by resulting quarter, the Solta organically the in Medical, sales for in grew
consistent year. growth with Our Asia been Pacific business throughout outside has the strong, of China
business China fourth quarter. to strong posted the in second growth and COVID lockdowns in in quarter the recover Our continued after the
segment competition, generic X% and by for for organic within margins by business for JUBLIA In growth last and are business focused remained full stable the strong declined impacted showed in for basis the by units the we the Both while on the Diversified, relative segment. stabilizing the our quarter. on quarter. the by the script an year year, to EBITDA Diversified XX% sales the growth Dermatology business XX% Dentistry has increased year, quarter for been and organic
Slide to X. Turning
a Let made in have along me back that the started alternative about we few progress make XXXX. we the strategic comments pathway
of progress in IPO completed of sheet. we the our balance May XXXX. in know, Since you then, As delevering Bausch + Lomb made we have
with the our net debt fourth by made which, previous During we to the open year successful and exchange executed in us repurchase we throughout market additional market QX, billion. closed reduce repurchases an the debt open enabled quarter, with we $X.X
strengthened the increased company's and on value We debt forward. to created XXXX. position, and have reduced XXXX also we our further financial has maturities our capitalize opportunities This as stakeholder move in flexibility
debt to reduction We matrix quarter. + continue the to since fourth The achieve stakeholder maximize evaluate potential L financial options did we in the required our + under IPO which unrestrict B in documents the has value. to Lomb, debt to significant Bausch enabled us
our debt + excluding in to portion by B further X.Xx of nonrecourse X.Xx have achieving efforts the it subsidiary, strengthen Lomb of implement shares. leverage Bausch which $X as us held to collateralized the resulted effective own is by to our L a Furthermore, unrestricted billion sheet our + relates net balance to transactions separation, targets,
to We ensuring Lomb of both and, financial therefore, stability We makes to to sense. remain of stand-alone companies companies basis. on a Bausch continue the believe the strong + committed creating X separation strategic
of as steps that full receipt necessary a achieve other addition, need approvals. there number including and remain previously be to shareholder of discussed, completed to In the separation,
results the improving a all So we related In performance relevant reinforcing operating remain evaluate foundation commercial B the L our separation. we for continually the to factors on + to thoughtfully solid meantime, focused and future.
the the January of settlement other to outcome are subject this not the IRS to several regard for make with to had is to approvals we it pleased year. the we results in do continue will mediation and the full before We the applied progress or expect Granite productive We we a matter. Through have a Lastly, with reached further review tentative although have the settlement IRS. fast-track -- finalized, a impact year cash the Trust, resolve flows. is company's settlement engagement to matters. With material on on
guidance of flow matter. cash potential the for reflects this Our XXXX impact
few Let a comments me with to make the Xifaxan litigation. respect
certain with disclosed patents and the valid previously XXXX, hepatic August As issued in Norwich a HE patents infringed Xifaxan-XXX Xifaxan encephalopathy, composition invalid. XX, finding we and court decision certain and have our on dispute IBS-D
filed have appeal. As disagree have stated, the we we certain court's decision portions of with an and
sought issued, would the judgment the of I decision was that court approve court's out XXXX. a permit court's decision until XXXX. like ANDA us remove has from However, filed approval that advised current Norwich prevents to the the point motion and FDA modify HE Since FDA the the indication receiving October to Norwich has to and to final final from to ANDA its has the before
and have await decision this We court. motion opposed from the a
the strength and to an remove IBS-D additional Xifaxan to receive issued the treatment patent Office for now Book protects remain the bioequivalent the for for to vivo FDA in Patent XXX biowaivers February XXX and patent issued of patents. We is confident now studies generics. Xifaxan further litigation all XXXX. XXX the opportunity about in supports are requires this say U.S. Orange Trademark Xifaxan guidance The Xifaxan and prepared an product is product-specific time. at Xifaxan generics This of U.S. rifaximin expires for portfolio. listed January we in patent the update Separately, that the and Xifaxan product our the XX, to On the
are turn XXXX share fourth XXXX I to over growth On of Tom to on we over a of Before for we XXXX, few second segments. significant the some across Vadaketh X half next level, in to discuss the call see Xifaxan guidance, is opportunity key there high starting drivers to the and Salix, momentum with I'd business the we the our pleased results the growth accelerate of Slide quarter XXXX and our believe years. like with
IBS-D are been by for IBS-D of and for large endorsed who indications. guidelines receiving recommended standard are both market and not still care a has HE is There treatment. and number patients large addressable The and both Xifaxan as across the HE of
consumers We significantly activate are increasing our in advertising for direct-to-consumer to HE. both and investment IBS-D
machine investing force in are learning. effectiveness artificial to sales and intelligence enhance We leveraging capabilities new
in are new expanding footprint to integrated delivery our with engage sales the institutional force We networks. space
variety a pharmacy executing new the experience. of both and access are improve provider initiatives to point-of-sale patient We
solidify will strong continue work payers proposition. We to Xifaxan's to with value
rifaximin. in invest to continue also We
the for pipeline, several have a complication our programs We a first program with Red-C associated of HE, episode including development in global cirrhosis. for the underway of prevention
this is for needs program, rights is only for trials address program in that for the track. than overt U.S. current patient much global Phase larger population RED-C today. the the market Xifaxan's which Enrollment global we HE, unmet which our in in III have clinical patient We population on
orphan designation formulation trial ongoing. rifaximin the program for clinical Phase for cell We are this II drug pleased also to sickle disease are and receive for in enrollments
pipeline, with amiselimod for we for are our colitis, Finally, our Salix UC. with suffering in study Phase progressing II patients ulcerative large
engagement psoriasis in Turning in Canada, our focusing growth profitable we to atopic are promotion, acne, digital direct-to-consumer International and efforts as well using programs. as dermatitis, In direct business. onychomycosis on our XXXX for dermatology
data We HCP our generation rapid offering enhanced turn to more understanding customers. customized to and an systems digital of our preferences leveraging in are management expanded enable insight generating
enhanced as sales well to aim education, training In drive marketing Europe, through we engagement our strong HCP as digital teams. growth continue continuous to and of
foam business, will UCERIS, colitis And and moderate launches into America, driving for ulcerative Benedorm, several expansion have launching brands. in In the allergic line Central across product an for America aerosol Bedoyecta for Latin Mexico. new Canada. of we we International extensions to are Ryaltris severe our launching with seasonal existing including distal in the rhinitis, be We
the is this business Medical, from attractive XX% a believe We growth markets Solta coming this in durable than more very that business revenue consumables. potential. significant of In strong, with has operating
in the in strengthening continue of Europe. reach through in geo our our the sales the of our Thermage presence and the FLX broadening expanding U.S., will We key including expansion direct-to-consumer markets, forces in to campaigns invest of
volume of the by optimistic in the recovery encouraged China, treatment pre-COVID procedures and in levels. the COVID the are We are we cautiously to of about lockdowns lifting
For Diversified, acne feedback. findings for presented new the and last dermatology of triple for November has at vulgaris. IDP-XXX Vegas conference in positive received product accepted the business, in Las drug IDP-XXX, the Dermatology the application for combination first in treatment our our We FDA Innovations
as We receive for approval. FDA of are launch as soon we product plans the finalizing this our
our manage In investing And products Seasonal to or more for patients diagnosed business effective portfolio our including a we in non-promoted in more Neurology antidepressant of efficient Aplenzin, business, be in this Disorder manner. we SAD. are broadly, with will and Affective looking
Finally, core acceleration in second Dentistry, with in an we treatment our Arestin condition see this periodontitis, large in of reinforced used by in of and to an the strategy product, our continue Arestin. We in on the a patient this saw population. suffered in expect XXXX. efforts benefit growth half commercial the XXXX antibiotic is
As you encouraging can programs exciting underway. see, we a number of and have
date, market R&D proud to needs. we drive that pipeline growth bring built ultimately are build momentum out the investments We revenue products to strategic to of to patient our and continue that make team has serve this and to
remainder turn will the our of fourth who Tom? outlook Tom will With to performance and an over details provide on that, year. the I quarter further for Vadaketh, the call
